PT  - JOURNAL ARTICLE
AU  - Vogelzang, Erik H.
AU  - Loeff, Floris C.
AU  - Derksen, Ninotska IL
AU  - Kruithof, Simone
AU  - Heer, Pleuni Ooijevaar-de
AU  - van Mierlo, Gerard
AU  - Linty, Federica
AU  - Mok, Juk Yee
AU  - van Esch, Wim
AU  - de Bruin, Sanne
AU  - Vlaar, Alexander P.J.
AU  - ,
AU  - Seppen, Bart
AU  - Leeuw, Maureen
AU  - van Oudheusden, Anne J.G.
AU  - Buiting, Anton G.M.
AU  - Jim, Kin Ki
AU  - Vrielink, Hans
AU  - Swaneveld, Francis
AU  - Vidarsson, Gestur
AU  - van der Schoot, C. Ellen
AU  - Wever, Peter
AU  - Li, Wentao
AU  - van Kuppeveld, Frank
AU  - Murk, Jean-Luc
AU  - Bosch, Berend Jan
AU  - Wolbink, Gerrit-Jan
AU  - Rispens, Theo
TI  - Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19
AID  - 10.1101/2020.06.17.20133793
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.17.20133793
4099  - http://medrxiv.org/content/early/2020/06/19/2020.06.17.20133793.short
4100  - http://medrxiv.org/content/early/2020/06/19/2020.06.17.20133793.full
AB  - SARS-CoV-2 infections often cause only mild disease that may evoke relatively low antibody titers compared to patients admitted to hospitals. Generally, total antibody bridging assays combine good sensitivity with high selectivity. Therefore, we developed sensitive total antibody bridging assays for detection of SARS-CoV-2 antibodies to the receptor-binding domain (RBD) and nucleocapsid protein (NP), in addition to conventional isotype-specific assays. Antibody kinetics was assessed in PCR-confirmed hospitalized COVID-19 patients (n=41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n=182), PCR-confirmed hospital care workers (n=47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n=14). In non-hospitalized patients, the antibody response to RBD is weaker but follows similar kinetics as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; NP antibodies emerged less consistently. Furthermore, we demonstrated the feasibility of finger prick sampling for antibody detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 antibodies in hospitalized and non-hospitalized patients, and are therefore well-suited to conduct seroprevalence studies.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been conducted in accordance with the ethical principles set out in the declaration of Helsinki and all participants provided written informed consent, if applicable. Approval was obtained from the Medical Ethics Committees from the Academic Medical Center, VU University Medical Center and Elisabeth-TweeSteden Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study are available upon reasonable request